Solid Biosciences is trading at $5.53, down 5.07%, amid broader market and biotech-sector pressure.

  • No verified October 14 company-specific announcement or catalyst emerged in available news; the prior session’s steep decline adds pressure.
  • Hotter-than-expected annual and core CPI readings lifted rate concerns as the Nasdaq and S&P 500 fell more than 0.5%.
  • XBI was down 2.01%, adding possible biotech-sector pressure; the move is best attributed to macro and sector factors, not a confirmed company event.